Gilead to lay off 110+ em­ploy­ees at for­mer Im­munomedics HQ in an­oth­er ding for its $21B deal

Af­ter a Phase III read­out for the cen­ter­piece of its $21 bil­lion Im­munomedics ac­qui­si­tion un­der­whelmed Wall Street, Gilead is bring­ing out the axe.

The Cal­i­for­nia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER